LRMR

Hamilton Thomas Edward

Known title: DirectorCIK: 0001769848

Hamilton Thomas Edward's purchase track record

How the stock did after each of Hamilton Thomas Edward's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.

Purchases measured
3
of 4 since September 16, 2022
Stock higher 6 months later
33%
3 months: 25%
Median 6-month return
-24.7%
3 months: -23.8%
Beat the S&P 500
33%
median -36.8% vs. index
PurchaseStockAmount3 months6 months
7/6/2026LRMR$167K-13.1%pending
2/27/2026LRMR$500K-34.5%-24.7%
2/16/2024LRMR$500K-42.3%-40.6%
9/16/2022LRMR$1000K+40.0%+68.1%

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 30, 2026

Larimar Therapeutics Names John Harlow as President and COO. Larimar Therapeutics has appointed John Harlow as its new President and Chief Operating Officer, effective September 29. This leadership change is intended to strengthen the company's executive team. The stock is currently trading near its 52-week low, which provides context for this operational update.

this person other insiders at LRMR

Transaction History

LRMR▲ Buy$167K
LRMR▲ Buy$500K
LRMR▲ Buy$500K
LRMR▲ Buy$1000K

We use analytics to understand how market-wall is used. No personal data is sold.